Ischemic stroke is a leading cause of adult disability with no pharmacological treatments to promote the recovery of lost function. Neutralizing antibodies against the neurite outgrowth inhibitor Nogo-A have emerged as a promising treatment for subacute and chronic stroke in animal models; however, whether anti-Nogo-A treatment affects poststroke neurogenesis remains poorly understood. In this study, we confirmed expression of Nogo-A by neuroblasts in the adult rat subventricular zone (SVZ), a major neurogenic niche; however, we found no evidence that Nogo-A was expressed at the surface of these cells. In vitro migration assays demonstrated that Nogo-A signaling induced a modest reduction in neuroblast migration speed, while anti-Nogo-A antibodies had no effect on motility properties. Using a permanent distal middle cerebral artery occlusion model of cortical stroke, we found that the number of proliferating cells in the SVZ was unaffected in response to stroke, while neuroblast mobilization from the SVZ toward the stroke lesion correlated positively with lesion size. However, we found no evidence that proliferation or neuroblast mobilization were affected by anti-Nogo-A antibody treatment. Our results suggest that the SVZ is not a therapeutic target of anti-Nogo-A immunotherapy, and contribute to our understanding of the SVZ response to cortical stroke.
INTRODUCTION
Ischemic stroke is a leading cause of adult disability (1) . Timely administration of tissue plasminogen activator (alteplase) or mechanical thrombectomy can improve long-term functional outcomes (2, 3) . However, many patients remain ineligible for these interventions and some degree of longterm physical impairment may occur in spite of treatment (3) .
Unfortunately, there are no pharmacological treatments available to promote the recovery of function lost to stroke. However, our laboratory and others have shown that treatment with neutralizing antibodies against Nogo-A, a protein that restricts anatomic and synaptic plasticity in the central nervous system, improves behavioral recovery after stroke in adult and aged rats ( [4] [5] [6] [7] [8] [9] [10] and reviewed in Ref. 11) . This recovery coincides with increased compensatory axonal sprouting from intact neural circuitry in anti-Nogo-A-treated rats (4, (8) (9) (10) 12) .
Nogo-A is a transmembrane protein with 2 active inhibitory domains, Nogo-66 and D20. Nogo-66 is contained within the C-terminal reticulon homology domain and is common to the 3 Nogo isoforms (A, B, and C), while D20 is located closer to the N-terminus and is specific to Nogo-A (reviewed in Ref. 13) . A member of the reticulon protein family, Nogo-A is localized primarily to the endoplasmic reticulum (14) (15) (16) (17) ; however, there is a small cell surface fraction expressed in certain cell types, such as oligodendrocytes, dorsal root ganglion neurons, and embryonic neural precursors (15, (17) (18) (19) , that is presumably available to signal to neighboring cells.
Multiple receptors for the Nogo-66 and D20 inhibitory domains of Nogo-A have been identified. Nogo-66 binds and activates Nogo receptor 1 (NgR1) and PirB, while D20 has been found to activate the sphingosine-1-phosphate receptor S1PR2 and inhibit the activity of specific integrins (20) (21) (22) (23) (24) . NgR1 and S1PR2 both activate the small GTPase RhoA, leading to activation of Rho-associated protein kinase (ROCK) and downstream cytoskeletal reorganization that underlies the inhibitory effects of Nogo-A (13). Furthermore, Nogo-A D20 signaling has been found to influence gene expression by reducing cAMP response element binding protein (CREB) phosphorylation (25) .
Beyond its well-known role as an inhibitor of neuronal plasticity, Nogo-A and its signaling partners have been implicated in diverse functions in the developing and adult nervous system (reviewed in Refs. 26 and 27) . For example, Nogo-A appears to regulate the migration of neuronal precursors in the embryonic brain (18, 28) , as well as the fasciculation and branching of nascent neurites (19, (28) (29) (30) . Neuronal Nogo-A has been found to inhibit angiogenesis in the developing brain (31) . As a therapeutic target, NgR1 blockade may promote behavioral recovery after white matter lesions in aged mice, concomitant with increased oligodendrocytic differentiation of oligodendrocyte progenitor cells (32) . NgR knockout mice exhibit increased hippocampal neurogenesis after traumatic brain injury (33) , although hippocampal neurogenesis is not appreciably altered by anti-Nogo-A neutralizing antibody treatment after stroke (34) .
A role for Nogo-A in the regulation of the subventricular zone (SVZ), one of the adult brain's main neurogenic niches, has also been described (35) . The SVZ contains neural stem cells that give rise to progenitors and ultimately neuroblasts, immature neurons that migrate via the rostral migratory stream (RMS) to the olfactory bulbs and integrate primarily as GABAergic interneurons (reviewed in Ref. 36 ). Specifically, Nogo-A was found to promote the migration of SVZ-derived neuroblasts toward the olfactory bulb, whereas NgR1 activation suppressed neural stem cell proliferation (35) . Key Nogo-A signaling partners, namely RhoA, ROCK and S1PR2, have also been investigated in the context of SVZ neurogenesis (37, 38) . ROCK inhibition was reported to increase the distance traveled by SVZ-derived neuroblasts in vitro and promote ectopic neuroblast migration away from the RMS in vivo, but did not affect neurogenesis after traumatic brain injury (39, 40) . After stroke, small molecule antagonism of the Nogo-A receptor S1PR2 was found to enhance the migration of SVZ neuroblasts toward a cortical lesion (41) .
Brain injury such as stroke may upregulate endogenous SVZ neurogenesis, and limited poststroke neuronal replacement from SVZ-derived precursors has been described (42) (43) (44) . Importantly, neurogenic processes may be involved in mitigating the extent of ischemic damage and promoting some degree of functional recovery (45, 46) . Therefore, endogenous neurogenesis is a potential therapeutic target for promoting repair after brain injury.
In light of the improved functional recovery by antiNogo-A antibody-treated animals after stroke and previous reports of Nogo-A involvement in SVZ neurogenesis, we examined the response of the SVZ to stroke and anti-Nogo-A neutralizing antibody treatment. We characterized the expression pattern of Nogo-A and its receptors in the adult rat SVZ and found that Nogo-A and S1PR2 were expressed by neuroblasts, while NgR1 expression was limited to ependymal cells. Moreover, we found no evidence that Nogo-A localized to the surface of SVZ neuroblasts, but that it instead colocalized with a marker of the endoplasmic reticulum. In vitro, Nogo-A-D20 signaling was found to reduce the maximum migration speed of SVZderived neuroblasts, while anti-Nogo-A antibody treatment itself had no significant effect on migration. Lastly, anti-Nogo-A antibody treatment did not result in any appreciable changes in either cellular proliferation within the SVZ or neuroblast mobilization from the SVZ after cortical stroke in vivo. These results suggest that Nogo-A likely plays a cell-autonomous role in SVZ neuroblasts, and that the SVZ response to stroke is not augmented by anti-Nogo-A immunotherapy.
MATERIALS AND METHODS

Animals and Approvals
All experiments involving animals were approved by the Institutional Animal Care and Use Committee of the Hines Veterans Affairs Hospital. Male Long-Evans black hooded rats (12 weeks old at study initiation; Harlan, Indianapolis, IN) were used in these experiments. Tissue from these animals was previously used in a separate study on hippocampal neurogenesis (34) . All animals were housed in pairs in a temperature and humidity-controlled facility with a 12-hour lightdark cycle. Food and water were provided ad libitum.
Anti-Nogo-A Antibody and Recombinant D20 Peptide Production
Mouse monoclonal anti-Nogo-A antibody 11C7 was produced from a hybridoma cell line provided by Prof. Martin Schwab (Brain Research Institute, University of Zurich). Antibody production and purification was performed as described in (34) . Briefly, protein-G column chromatography was used to purify the 11C7 antibody from antibody-containing medium (Pierce, Waltham, MA). Purified 11C7 was further diluted to 2.5 mg/mL in sterile phosphate-buffered saline for infusion.
The pET28 expression vectors containing His/T7-tagged Nogo-A-D20 (rat aa 544-725) or scrambled (SCR)-D20 were generously provided by Prof. Martin Schwab. To generate recombinant proteins, BL21 (DE3) Escherichia coli (Invitrogen, Carlsbad, CA) were transformed with each vector and cultured at 37 C in 2-YT broth/kanamycin until an OD 600 ¼ 0.6-0.8 was reached ($2.5 hours). Protein expression was induced by the addition of 1M IPTG for 4 hours at 30 C. The tagged proteins were purified using TALON metal affinity resin (Clontech, Mountain View, CA). The purified proteins were quantified by absorbance at 280 nm. The authenticity of the 2 recombinant proteins was verified by their migration on polyacrylamide gels and their reactivity to an antiT7 antibody (EMD-Millipore, Billerica, MA) and the Nogo-A-specific 11C7 antibody, whose epitope is within the Nogo-A-D20 amino acid sequence.
SVZ Explant Culture and Migration Assays
The method for SVZ explant culture was adapted from (47) . Three-to 4-month-old male Long-Evans black hooded rats were deeply anesthetized with inhalant isoflurane and decapitated. The brains were then rapidly extracted and placed in cold phosphate-buffered saline on ice and 300-lm coronal sections were then cut on a vibratome and placed in sterile HEPES-buffered artificial CSF on ice. Under a dissecting microscope, 500 lm diameter tissue punches were taken from the SVZ and transferred onto tissue culture dishes that had been precoated with a 3:1 mixture of growth factor-reduced Matrigel (Corning, Corning, NY):Neurobasal-A (Gibco, Waltham, MA) medium. Explants were isolated as matched pairs, so that a treated explant was paired with a control explant from the same position within the SVZ on the contralateral side. Once all explants were collected, the plates were placed in a 37 C incubator for 5-10 minutes to allow the Matrigel to congeal. Afterwards, the explants were overlaid with media composed of Neurobasal-A, 2% B27 without vitamin A (Gibco), 2 mM Glutamax (Gibco), and penicillin-streptomycin, plus either anti-Nogo-A or anticyclosporine-A control antibodies (50 lg/mL) or Nogo-A-D20 or scrambled D20 sequence recombinant peptides (500 nM). Plates were stored in a 37 C cell culture incubator supplemented with 5% CO 2 . Media changes were performed 3 days later with resupplementation of antibodies or peptides. Time-lapse videos of migrating cells were acquired between 3 and 5 days in vitro. Images were acquired every 5 minutes for 6 hours using a Zeiss Axiovert microscope with 10x objective in a humidified chamber maintained at 37 C with 5% CO 2 . Cells were tracked either manually using phase contrast videos or using a semiautomated technique based on the movement of Hoechst dye-stained nuclei. In the latter case, cells were labeled with Hoechst 33342 DNA dye (25 nM; Thermo Fisher, Waltham, MA) the night before imaging. To mitigate phototoxicity, the cells were imaged using the lowest lamp power possible. In our hands, this combination of Hoechst 33342 concentration, lamp power, and imaging frequency resulted in minimal toxicity as measured by qualitative assessment of the long-term health of the cultures and low level of apoptosis observed during live cell imaging. Cells undergoing apoptosis were easily visualized due to nuclear condensation and/or fragmentation and were excluded from analysis.
Cell videos were imported into ImageJ (48) and manually tracked by an investigator blinded to treatment group using the TrackMate (49) or mTrackJ plugins. In TrackMate, cell tracking can be semi-automated based on automatic detection of cell nuclei in successive video frames. In all cases, cells were tracked one at a time to ensure accuracy. Neuroblast nuclei (small, bright, round to oblong in shape) were visually distinct from the nuclei of astrocytes that had migrated out of the explant (larger, dimmer). Due to the difficulty of distinguishing cells in chains, especially closer to the explant, only singly migrating cells were tracked. These cells were typically located on the periphery of the halo of migrating cells and displayed the unipolar to bipolar morphology of migrating neuroblasts. As phase contrast images were also acquired for each time point, nuclei could be referenced against cell morphology if the identity of the cell (neuroblast vs astrocyte) was not clear. Maximum and average migration speeds for each cell were computed by the software based on the change of cell position over time.
From each explant, between 11 and 60 cells were tracked. As each matched explant pair (treatment and control) was obtained from a different animal, each pair was treated as a single independent experiment.
Stroke Surgeries
Permanent distal middle cerebral artery occlusion (MCAO) was performed as previously described (6, 8, 12, 34) . Briefly, under 2% isoflurane anesthesia, an incision was made through the left scalp and temporalis muscle. A craniotomy was then performed to visualize the middle cerebral artery (MCA). The MCA was ligated with 10-0 suture and transected. The left common carotid artery (CCA) was isolated via a midline neck incision and permanently ligated with 4-0 suture, and the right CCA was transiently occluded for 1 hour using an aneurysm clip. Body temperature was maintained at 37 C throughout the procedure. Incisions were sutured and animals were allowed to recover in their home cage. Sham surgery animals were identically anesthetized for an equivalent duration and received neck and scalp incisions.
Intracerebroventricular Antibody Treatment
Treatment was performed as previously described (7, 8, 34) . Briefly, 1 week following stroke, rats were anesthetized with and implanted with subcutaneous osmotic minipumps (Alzet model 2ML2; Durect Corporation, Cupertino, CA) to deliver antibody via a cannula into the ipsilesional lateral cerebral ventricle. Antibodies, either anti-Nogo-A antibody 11C7 or a control mouse IgG1 raised against cyclosporine-A (a generous gift from Novartis International AG [34, 50] ), were infused at a rate of 5 lL/hour (12.5 lg/hour) for 14 days.
Tissue Processing and Immunostaining
On poststroke day 21 (i.e. at the end of 14 days of antibody treatment), rats received a single 200 mg/kg intraperitoneal injection of 5-bromo-2 0 -deoxyuridine (BrdU) (SigmaAldrich, St. Louis, MO) prepared at 20 mg/mL in sterile saline plus 0.007 N NaOH) 2 hours prior to death. Rats were killed by overdose with Euthasol (390 mg/kg i.p., Virbac, Fort Worth, TX) and transcardially perfused with cold heparinized saline followed by 4% paraformaldehyde prepared in phosphate buffer. Brains were extracted and postfixed overnight in 4% paraformaldehyde in phosphate buffer, then cryoprotected in 30% sucrose until sinking. Brains were then embedded in OCT and cryosectioned at 40 lm using a Leica CM1850 cryostat. Sections were stored in antifreeze solution at À20 C until further processing.
See Table 1 for antibodies and dilutions used in these studies. For BrdU immunostaining, tissue sections were first immersed in sodium citrate pH 6 at 99 -100 C for 15 minutes (34, 51). Phosphate-buffered saline pH 7.4 plus 0.2% Tween-20 was used as an antibody incubation and washing buffer for all subsequent steps whenever this high heat antigen retrieval procedure was used. Otherwise, phosphate buffer pH 7.4 plus 0.4% Triton-X100 was used for all other staining procedures not requiring antigen retrieval. Sections were incubated in primary antibody solution for 24-48 hours at 4 C, and then washed extensively. Incubation in secondary antibody solution was performed for 2 hours at room temperature, followed by extensive washing and counterstaining with 4 0 ,6-diamidino-2-phenylindole (DAPI). Sections were mounted on slides and coverslipped with Fluoromount-G media (Southern Biotech, Birmingham, AL). For S1PR2 staining, a biotinylated secondary antibody was used, followed by incubation in avidin-biotin peroxidase complex (VectaStain Elite ABC Kit; Vector Laboratories, Burlingame, CA) and AlexaFluor 568 tyramide solution (Thermo Fisher Scientific) per manufacturer's instructions.
Chromogenic doublecortin (DCX) labeling for quantifying neuroblast mobilization was performed with the following modifications. Tissue was incubated in rabbit antiDCX antibody solution (Cell Signaling Technology; 1:5000), followed by a goat antirabbit biotinylated secondary antibody and finally avidin-biotin peroxidase complex. The signal was then developed using nickel-enhanced 3,3 0 -diaminobenzidine ([DAB] Sigma-Aldrich). Tissue sections were mounted on gelatin-subbed slides, dehydrated in graded ethanols, cleared in xylene, and coverslipped with Permount (Fisher Scientific, Waltham, MA).
Live cell surface staining was performed as follows (adapted from Ref. 15 ). SVZ explants were first plated on glass coverslips precoated with 50 lg/mL laminin (Sigma Aldrich) in Neurobasal-A, 2% B27 without vitamin A, 2 mM Glutamax, and penicillin-streptomycin, and incubated in a 37 C incubator supplemented with 5% CO 2 . Once explants adhered and cells began migrating outward onto the coverslips, the coverslips were rinsed once with room temperature PBS, then once with cold PBS and placed on ice. Primary antibodies (anti-Nogo-A antibodies 11C7 or 7B12) were applied at a concentration of 25 lg/mL in PBS plus 5% fetal bovine serum on ice for 30 minutes. The coverslips were then washed 3 times in cold PBS and fixed in 4% paraformaldehyde on ice for 30 minutes. Cells were then incubated in rabbit antiDCX antibody under membrane-permeabilizing conditions (1:500 in PBS plus 5% normal goat serum and 0.1% Triton-X100) overnight at 4 C. The following day, the coverslips were washed, incubated in fluorescent secondary antibodies against rabbit (DCX) and mouse (11C7 or 7B12) IgG, washed again, and mounted on slides with Fluoromount G mounting media. Cells were imaged using a Leica SPE confocal microscope.
Immunofluorescence on fixed, permeabilized cells was performed with the following modifications. Cells were fixed with 4% paraformaldehyde for 30 minutes on ice, then washed with PBS and blocked in PBS plus 5% normal goat serum and 0.1% Triton-X100 for 1 hour at room temperature. Primary antibodies were applied overnight in blocking buffer. The following day, coverslips were washed in PBS and incubated in fluorescent secondary antibodies in blocking buffer. After counterstaining with DAPI and washing, coverslips were mounted on slides with Fluoromount G mounting media. 
Assessment of SVZ Cellular Proliferation In Vivo
To quantify proliferation, a 1-in-6 series of 40-lm sections per subject, beginning rostrally at the genu of the corpus callosum (bregma þ2.2) and proceeding caudally to the crossing of the anterior commissure (bregma þ0) (8 total sections), was included for analysis. Cells were immunostained for BrdU as described and nuclei were counterstained with DAPI. BrdU-positive cells in the SVZ were quantified stereologically using the optical fractionator probe in MBF StereoInvestigator software (MBF Biosciences) interfaced with a Leica DM4000B epifluorescence microscope with a 63Â/0.7 NA objective. For drawing counting contours, the SVZ was defined as the dense band of DAPI-stained nuclei in the lateral wall of the lateral ventricles, extending from the dorsal-most point of the lateral ventricle, including the dorsolateral extension of the SVZ, and extending ventrally to the ventral-most point of the lateral ventricle.
Assessment of SVZ Neuroblast Mobilization In Vivo
Analysis of in vivo neuroblast mobilization was performed at 21 days poststroke (i.e. at the end of a 14 day treatment regimen). For each subject, a 1-in-6 series of 40-lm-thick sections between the genu of the corpus callosum and the crossing of the anterior commissure (8 sections total per subject) was stained for DCX, a marker of immature neurons in the SVZ. DCXþ cells were manually counted by an analyst blind to experimental group in the striatum and corpus callosum/external capsule (white matter) bilaterally. Cells were counted when they satisfied the following criteria: (1) Adequately stained cell body and processes, with staining intensity comparable to the intensity seen within the SVZ itself (i.e. "obviously" stained cells); (2) Cell body located at least 100 lm from the border of the SVZ, the SVZ defined as the contiguous expression of DCX-positive cells, including into the dorsolateral extension of the SVZ; and (3) DCX-positive processes were not counted if their associated cell body was not visible. This counting procedure is stringent and likely underestimates the total population. The cell counts for each section were summed and multiplied by 6 to estimate the total population within the regions of interest. Sham counts were obtained by counting in these regions of interest bilaterally and taking the mean of the 2 sides.
Statistics
Statistical analysis was performed in GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA). Normality of the data was assessed using a D'Agostino and Pearson test for normality followed by analysis using parametric tests when normality was confirmed, or nonparametric tests when normality was not confirmed. For comparisons of 3 or more groups, oneway ANOVA or Kruskal-Wallis tests were performed. For comparisons of in vitro cell motility properties, explants were analyzed as matched pairs, with motility from a treated explant compared to motility from a control explant isolated from the same anatomic location on the contralateral side of a single coronal brain section. In these cases, sample sizes were derived from the total number of animals from which explants were harvested (n ¼ 5-7) and paired t-tests were used to assess statistical significance. Comparisons were considered statistically significant at p < 0.05.
RESULTS
Expression Pattern of Nogo-A and Its Receptors S1PR2 and NgR1 in the Adult Rat SVZ Nogo-A was found to be strongly expressed in the adult rat SVZ (a simplified schematic of lineage progression and marker expression [36, 52] is shown in Fig. 1A) . As previously reported in adult mice (35) , double label immunofluorescence revealed Nogo-A expression by DCX-positive neuroblasts (Fig. 1B-D) , but not GFAP-positive stem cells or astrocytes (Fig. 1E) . While S1PR2 was broadly expressed in the SVZ, including in DCX-positive neuroblasts (Fig. 1F) , we found no clear evidence of NgR1 labeling within the rat SVZ and no expression by GFAP-positive cells (Fig. 1G) . However, we did observe punctate NgR1 labeling at the apical surface of the ependymal cell layer (Fig. 1H) . On the other hand, as expected, NgR1 labeling was seen in cortical and striatal neurons within these same tissue sections (not shown). These results suggest that SVZ neuroblasts may be subject to regulation by Nogo-A signaling.
Lack of Evidence for Expression of Nogo-A at the Neuroblast Cell Surface
Nogo-A is a reticulon protein that localizes primarily to the endoplasmic reticulum, but can be found at the surface of certain cell types where it is available to signal to other cells (reviewed in Ref. 26 ). To determine whether Nogo-A is expressed at the surface of SVZ-derived neuroblasts, live nonpermeabilized SVZ cultures were stained with Nogo-Aspecific antibodies on ice as previously described by others (15) . This method limits antibody binding specifically to extracellular epitopes. Using 2 different Nogo-A-specific antibodies (monoclonal antibodies 11C7 and 7B12, directed against different epitopes near the N-terminus of Nogo-A [ Fig. 2A]) , we found no evidence of surface labeling of DCX-positive cells (Fig. 2B, C) . We did find DCX-negative cells with clear, punctate Nogo-A labeling at the cell surface, which served as an internal positive control for this live-cell labeling method (Fig.  2C, arrowhead) . In contrast, under control conditions in which cells were fixed and permeabilized prior to all labeling steps, DCX-positive cells labeled strongly for Nogo-A (Fig. 2D ), in accordance with our in vivo immunofluorescence studies.
Next, we used an antibody against the ER marker calnexin (28) to investigate the subcellular distribution of Nogo-A in SVZ-derived neuroblasts. We found that calnexin colocalized reliably with Nogo-A in DCXþ cells, from the cell soma to the distal processes (Fig. 2E) .
These results suggest that while Nogo-A is expressed by SVZ-derived neuroblasts, it is localized primarily if not exclusively intracellularly. Furthermore, Nogo-A and calnexin colocalize in this cell type, suggesting association of Nogo-A with the endoplasmic reticulum. 
Chronic Nogo-A Signaling Modestly Slows Neuroblast Migration
To assess the role of Nogo-A signaling in SVZ neuroblast migration, explants from the adult rat SVZ were cultured (Fig. 3A) and treated with either anti-Nogo-A antibody (or control antibody), or recombinant, monomeric Nogo-A-D20 peptide (or scrambled control peptide). Using time-lapse video microscopy ( Fig. 3B) , we found a modest but statistically significant reduction in neuroblast maximum speed (p ¼ 0.021, paired t-test), and a trend toward a decreased average speed (p ¼ 0.063, paired t-test) in explants treated chronically with recombinant D20 peptide (Fig. 3C, D ; Table 2 ). Conversely, we found no significant effect of anti-Nogo-A antibody treatment on either average or maximum neuroblast migration speed (Fig. 3E, F) . These data suggest that Nogo-A signaling plays a role in fine-tuning the speed of neuroblast migration, but that anti-Nogo-A antibody does not exert a direct effect on neuroblast motility.
Stroke Mobilizes Neuroblasts, but Does Not Alter the Number of Proliferating Cells in the SVZ
To analyze the response of the SVZ to stroke and antiNogo-A treatment, stroke was induced by permanent distal middle cerebral artery occlusion followed 7 days later by 14 days of antibody treatment. As we have previously reported (34) , stroke lesion sizes were not affected by anti-Nogo-A treatment (stroke-only: 18.3% 6 2.4%; stroke plus control antibody: 20.5% 6 1.2%; stroke plus anti-Nogo-A antibody: 16.3% 6 2.4% represented as mean percentage of intact hemisphere 6 SEM; F(2,16) ¼ 0.339, p ¼ 0.40, one-way ANOVA). A representative image of lesion location with respect to the SVZ is shown in Figure 4 .
Stroke itself did not significantly affect the number of proliferating (BrdUþ) cells in either the ipsilesional or contralesional SVZ vs sham surgery measured at 21 days poststroke ( Fig. 5A , B; Table 3 (Fig. 5B) . We also found no indication of increased cellular proliferation at earlier time points (data not shown).
Next, we assessed neuroblast mobilization toward the stroke lesion by counting DCXþ cells that had left the SVZ and migrated into the striatum or white matter tracts of the corpus callosum and external capsule. Scattered DCXþ cells with elongated morphology suggestive of migrating neuroblasts were seen within the striatum and corpus callosum/external capsule between the SVZ and stroke lesion (Fig. 6A, middle panel) . As in uninjured animals, these cells expressed Nogo-A (Fig.  6B) , which was especially prominent in the leading process. Within the white matter, these cells generally appeared to align with the fibers coursing through these tracts. While stroke mobilized neuroblasts from the SVZ, the number of ectopic DCXþ cells in the striatum and white matter was not further altered by antibody treatment (Fig. 6C, D ; Table 4 ). However, the number of ectopic neuroblasts in the ipsilesional white matter of all treatment groups combined correlated positively with lesion size (Fig. 6E; Pearson's 
These results suggest that anti-Nogo-A antibody treatment does not appreciably alter the mobilization of neuroblasts from the SVZ towards the cortical infarct. However, neuroblasts are recruited more robustly toward larger stroke lesions in our model.
DISCUSSION
Therapies targeting the neurite outgrowth inhibitor Nogo-A have emerged as promising treatments for promoting functional recovery after stroke (reviewed in Ref. 11). Previous studies have focused mainly on the ability of anti-Nogo-A antibody treatment to enhance anatomical plasticity, in particular compensatory growth and sprouting from intact neural circuitry (4, 9, 10, 53) . This enhanced remodeling is believed to be critical for behavioral recovery in animals treated with anti-Nogo-A antibodies after stroke (10) . While the exact targets responsible for the efficacy of anti-Nogo-A antibody treatment are not fully known, oligodendrocyte-expressed Nogo-A appears to be particularly important for restricting plasticity in the adult CNS, and Nogo-A has been shown to localize to the surface of oligodendrocytes where it may be targeted by therapeutic antibodies (54) (55) (56) . However, Nogo-A also appears to be involved in numerous other physiological processes in both the developing and adult CNS. Notably, both embryonic and adult neurogenesis have been reported to be subject to regulation by Nogo-A (18, 28, 35) . However, whether poststroke neurogenesis is influenced by anti-Nogo-A immunotherapy is poorly understood. In this study, we focused on the SVZ, a major neurogenic niche along the walls of the cerebral lateral ventricles that generates thousands of new olfactory bulb interneurons each day in rodents (36) . Importantly, ectopic neuroblast emigration from the SVZ may contribute to neuronal replacement and play a role in recovery after stroke in animal models (42, 45, 46) . This study therefore examined whether anti-Nogo-A immunotherapy augments the response of the adult rat SVZ to stroke. We first established the expression patterns of Nogo-A and its receptors in the adult rat SVZ in vivo. In accordance with previously published work in adult mice (35) , Nogo-A was found to be strongly expressed by DCX-positive neuroblasts in the SVZ, but not by GFAP-positive neural stem cells or astrocytes. The Nogo-A D20 domain receptor S1PR2 was broadly expressed, including in SVZ neuroblasts. In contrast, expression of the Nogo-66 receptor NgR1 was limited to the apical surface of the ependymal cell layer, with immunolabeling appearing as discrete punctate clusters. No cell-specific labeling for NgR1 was apparent in the SVZ, although cells in other brain regions were labeled in these same tissue sections. These observations raise 2 main issues. First, we were unable in this study to confirm NgR1 expression in the adult rat SVZ, as has been reported in mice (35) . Second, the functional significance of NgR1 expression by ependymal cells is unknown, although its striking expression pattern in this cell type suggests a possible relationship to ependymal cell cilia.
Once we established that Nogo-A expression in the SVZ was limited to neuroblasts, we used live-cell staining to examine whether the N-terminal epitopes recognized by therapeutic anti-Nogo-A antibodies were expressed at the surface of this (15, 18) . Other cell surface molecules, including PSA-NCAM and certain integrins, may be involved in the migration of neuroblasts from the SVZ to the olfactory bulb via the RMS (57) . As these neuroblasts form close homotypic contacts ("chains") in the RMS (36), they are well-positioned to signal to and regulate neighboring cells. Our results suggest that Nogo-A D20 is likely not involved in intercellular signaling within these homotypic chains. However, cell-autonomous roles for Nogo-A have also been proposed. Intracellular Nogo-A may influence ER structure (14, 58) , signaling (59) , and/or neuronal development and neurite branching (19, 29, 30, 60) , suggesting multiple opportunities for cell-autonomous regulation of neuroblasts by Nogo-A. Our data showing a lack of surface expression of Nogo-A by SVZ neuroblasts does not preclude a role for extrinsic Nogo-A signaling in the regulation of these cells. Indeed, we found that recombinant Nogo-A D20 peptide reduced the maximum velocity of migrating SVZ neuroblasts in vitro. The functional significance of Nogo-A-mediated reduced neuroblast migration speed was not addressed in this study. However, precise regulation of neuroblast migration may be necessary for proper neuronal maturation and circuit development (38, 61) .
Our data on migration speeds are in accordance with previous reports, though due to technical limitations, we did not analyze chain-migrating neuroblasts, which migrate faster than single cells (47) . Migration from the SVZ to the olfactory bulb occurs largely as tangential chain migration. Once in the olfactory bulb, neuroblasts dissociate to travel radially into deeper olfactory bulb layers as single cells (36) . Different intracellular signaling pathways may mediate these 2 distinct migration modes-for example, the Rho effector mDia has been found to regulate tangential but not radial migration (37) . Therefore, it is possible that Nogo-A signaling may differentially affect properties of chain-and singly migrating cells, which was not addressed in this study.
In accordance with a lack of cell surface localization of Nogo-A in SVZ neuroblasts, we found no direct effect of antiNogo-A antibody on the motility of these cells, as would be expected if there was no exposed epitope available for the antibody to bind. However, whether in vivo antibodymediated neutralization of surface Nogo-A on other cell types (eg oligodendrocytes) affects the motility of SVZ neuroblasts remains to be determined.
Endogenous neurogenesis is particularly relevant in the context of brain repair. For example, cellular proliferation in the SVZ is upregulated in certain models of stroke (62) . After stroke, neuroblasts may leave the SVZ and migrate toward injured tissue under the direction of locally released chemokines, including SDF1a, angiopoietin, MCP-1, and osteopontin (58) . As numerous preclinical studies from our laboratory and others have demonstrated the efficacy of antiNogo-A immunotherapy in promoting sensorimotor and cognitive recovery after stroke (4) (5) (6) (7) (8) (9) (10) 12) , in an in vivo study, we set out to determine whether anti-Nogo-A immunotherapy could boost poststroke cellular proliferation or neuroblast mobilization from the SVZ. Using the same stroke model and treatment regimen previously shown to promote behavioral recovery, we used BrdU pulse labeling and DCX immunohistochemistry to quantify cellular proliferation and neuroblast emigration, respectively. Our stereological BrdUþ cell count data from our sham surgery group (i.e. baseline proliferation in the rat SVZ) are in accordance with a previous report regarding the number of proliferating cells in the adult rat SVZ (63) . However, the reaction of the SVZ to our stroke model (distal middle cerebral artery occlusion in adult rats) was subtle. Using unbiased stereological cell counting, we found no effect of the stroke itself on the number of proliferating cells in the SVZ at 21 days after stroke. While this time point may be beyond the reported peak of poststroke proliferation in the SVZ (64) , pilot studies performed in our laboratory at 5, 10, and 14 days poststroke have suggested no evidence of stroke-induced increases in proliferation at these earlier time points (data not shown). Our finding of a lack of a proliferative response of the SVZ to cortical ischemia is in line with a recently published study in mice showing unchanged numbers of proliferating cells after cortical stroke (65) .
Furthermore, only scattered DCX-positive neuroblasts were seen migrating within the ipsilesional striatum and white matter toward the lesion after stroke. We classified these cells as neuroblasts based on their unipolar to bipolar morphology and dark DCX staining, reminiscent of cells within the SVZ itself. These mobilized neuroblasts continued to express Nogo-A, which was especially prominent in the leading process. Notably, this subcellular expression pattern of Nogo-A was similar to an observation made by Mingorance-Le Meur and colleagues regarding Nogo-A expression in tangentially migrating interneuron precursors in the embryonic brain (28) . The significance of this subcellular localization is unclear, but we postulate based on the in vitro staining pattern that this reflects the association of Nogo-A with the endoplasmic reticulum.
The number of neuroblasts mobilized into the ipsilesional white matter correlated positively with lesion size. We also observed an increase in the number of neuroblasts entering the ipsilateral striatum after stroke, though this did not reach statistical significance. These data suggest that in our model, the SVZ responds to cortical stroke through diversion of neuroblast migration, but not increased proliferation.
In examining treatment effects, we found no evidence that either proliferation or neuroblast mobilization were altered by the infusion of anti-Nogo-A antibodies. Rolando and colleagues previously showed in adult mice that effects of Nogo-A signaling in the SVZ are domain-specific: The Nogo-A D20 domain promoted the migration of neuroblasts to the olfactory bulb, whereas activation of NgR1 suppressed neural stem cell proliferation (35) . Our therapeutic anti-Nogo-A antibody (mAb 11C7) specifically targets the D20 domain of Nogo-A. However, the infusion of this antibody has been shown to downregulate total Nogo-A in a dose-dependent manner (66) . If total Nogo-A is downregulated in our treatment paradigm, the presence of redundant NgR1 ligands (eg myelin-associated glycoprotein and oligodendrocyte myelin glycoprotein [13] ) may account for the lack of a proliferative response to mAb 11C7 treatment.
In conclusion, our data show that Nogo-A is robustly expressed by neuroblasts in the adult rat SVZ, and that neuroblast migration speed may be reduced by Nogo-A signaling. However, treatment with anti-Nogo-A antibodies after stroke, previously shown to promote behavioral recovery, did not result in any appreciable changes in proliferation within the SVZ or neuroblast mobilization toward the stroke lesion. Therefore, SVZ-derived neurogenesis is unlikely to contribute significantly to the recovery seen after stroke and anti-Nogo-A immunotherapy. Rather, other mechanisms, in particular anatomical plasticity of intact circuitry, appear to be responsible for behavioral improvement.
